comparemela.com

Latest Breaking News On - Safety monitoring - Page 14 : comparemela.com

PureTech Reports Results from Phase 2 Study of LYT-100-COV in Post-Acute Long COVID with Respiratory Complications

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announced results from a Phase 2 study of LYT-100-COV (deupirfenidone) in .

Hong Kong Government Pays HK$2 Million for a Vaccine-Related Death

Aptose to Provide Program Updates at KOL Webinar on Thursday, June 2nd

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.